Last week’s hot topic on pulmonary fibrosis was NY Times Covers Story of IPF Patient’s Progress with Esbriet Treatment written by Isaura Santos.
This article follows a story covered by the NY Times, about an IPF patient’s progress with Esbriet treatment. “I’ve experienced no change in my condition, no major deterioration since I started on Esbriet,” says Daniel Castner in an exclusive interview with The New York Times. “When I was first diagnosed, I started thinking about the last things I’d get to see before I died,” he said in the interview. “Now I don’t think about death.”
Esbriet (pirfenidone), marketed by Roche through its subsidiary Genentech, is an anti-fibrotic drug thought to act by decreasing the production of collagen and growth and inflammatory factors, ultimately leading to a reduction in lung fibrosis.